




Searching News Database: Huntington
HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
HSMN NewsFeed - 11 Mar 2019
Alcyone Lifesciences Receives Breakthrough Device Designation from U.S. FDA for the ThecaFlex DRx(TM) System
Alcyone Lifesciences Receives Breakthrough Device Designation from U.S. FDA for the ThecaFlex DRx(TM) System
HSMN NewsFeed - 23 Aug 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
HSMN NewsFeed - 11 Jul 2017
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
HSMN NewsFeed - 27 Jun 2017
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
HSMN NewsFeed - 3 Aug 2015
Omidria(R) Approved for Commercialization Throughout the European Union and Additional Countries
Omidria(R) Approved for Commercialization Throughout the European Union and Additional Countries
HSMN NewsFeed - 30 Sep 2013
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
HSMN NewsFeed - 4 Mar 2013
Symmetry Surgical Unveils Next Generation Bookwalter(R) Self-Retaining Rotilt Ratchet
Symmetry Surgical Unveils Next Generation Bookwalter(R) Self-Retaining Rotilt Ratchet
HSMN NewsFeed - 27 Feb 2013
Symmetry Surgical Continues European Presence With Distributor in the United Kingdom
Symmetry Surgical Continues European Presence With Distributor in the United Kingdom
HSMN NewsFeed - 8 Jan 2013
Absorption Pharmaceuticals Names Laurence A. Levine, MD As The Company's Chief Medical Officer
Absorption Pharmaceuticals Names Laurence A. Levine, MD As The Company's Chief Medical Officer
HSMN NewsFeed - 28 Aug 2012
Symmetry Medical Announces FDA Clearance of Its FLASH PAK(R) Evolution Valve
Symmetry Medical Announces FDA Clearance of Its FLASH PAK(R) Evolution Valve
HSMN NewsFeed - 25 Jun 2012
Symmetry Medical Launches Complementary Additions to Its Micro Instrument Portfolio
Symmetry Medical Launches Complementary Additions to Its Micro Instrument Portfolio
HSMN NewsFeed - 14 Dec 2011
Interleukin Genetics Appoints Lynn Doucette-Stamm Vice President of Development
Interleukin Genetics Appoints Lynn Doucette-Stamm Vice President of Development
HSMN NewsFeed - 12 Dec 2011
Symmetry Medical to Acquire the Surgical Instruments Business of Codman & Shurtleff
Symmetry Medical to Acquire the Surgical Instruments Business of Codman & Shurtleff
HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
HSMN NewsFeed - 20 Sep 2011
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
HSMN NewsFeed - 24 Jun 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Appoints Kathlene L. Powell Vice President, Quality Operations
Raptor Pharmaceutical Appoints Kathlene L. Powell Vice President, Quality Operations
HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
HSMN NewsFeed - 24 May 2010
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
HSMN NewsFeed - 10 Dec 2009
Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
HSMN NewsFeed - 2 Dec 2009
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
HSMN NewsFeed - 29 Jul 2009
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
HSMN NewsFeed - 28 Jul 2009
Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
HSMN NewsFeed - 11 May 2009
Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
HSMN NewsFeed - 13 Apr 2009
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
HSMN NewsFeed - 19 Mar 2009
Cortex Pharmaceuticals Announces Corporate Restructuring and Workforce Reduction
Cortex Pharmaceuticals Announces Corporate Restructuring and Workforce Reduction
HSMN NewsFeed - 18 Feb 2009
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
HSMN NewsFeed - 4 Feb 2009
Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
HSMN NewsFeed - 12 Dec 2008
Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
HSMN NewsFeed - 2 Dec 2008
Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures
Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures
HSMN NewsFeed - 1 Dec 2008
Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US
Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US
HSMN NewsFeed - 10 Nov 2008
Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO
Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO
HSMN NewsFeed - 17 Sep 2008
Cambridge Laboratories Announces New Marketing Arrangements for XENAZINE(R) in North America
Cambridge Laboratories Announces New Marketing Arrangements for XENAZINE(R) in North America
HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
HSMN NewsFeed - 18 Aug 2008
Cambridge Laboratories Announces FDA Approval of XENAZINE(R) (tetrabenazine) in the US
Cambridge Laboratories Announces FDA Approval of XENAZINE(R) (tetrabenazine) in the US
HSMN NewsFeed - 15 Aug 2008
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
HSMN NewsFeed - 24 Jul 2008
Medivisor Inc. Announces New Sales and Marketing Agreement for Mucotrol(TM) With Cura Pharmaceutical Co Inc.
Medivisor Inc. Announces New Sales and Marketing Agreement for Mucotrol(TM) With Cura Pharmaceutical Co Inc.
HSMN NewsFeed - 9 Jun 2008
Curlin Medical Awarded Three-Year Pain Management - Local Anesthetic Contract by Premier, Inc.
Curlin Medical Awarded Three-Year Pain Management - Local Anesthetic Contract by Premier, Inc.
HSMN NewsFeed - 9 Jun 2008
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
HSMN NewsFeed - 27 May 2008
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
HSMN NewsFeed - 9 May 2008
Hospitals, Healthcare Systems to Save with Premier New Pain Management, Local Anesthetic Agreements
Hospitals, Healthcare Systems to Save with Premier New Pain Management, Local Anesthetic Agreements
HSMN NewsFeed - 20 Feb 2008
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 4 Feb 2008
Misonix Announces Distribution Agreement for New BoneScalpel(TM) Medical Device
Misonix Announces Distribution Agreement for New BoneScalpel(TM) Medical Device
HSMN NewsFeed - 29 Jan 2008
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
HSMN NewsFeed - 13 Dec 2007
Neurologix Gene Therapy Approach to Parkinson's Disease Granted Fast Track Designation From FDA
Neurologix Gene Therapy Approach to Parkinson's Disease Granted Fast Track Designation From FDA
HSMN NewsFeed - 19 Nov 2007
Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program
Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program
HSMN NewsFeed - 12 Nov 2007
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
HSMN NewsFeed - 31 Oct 2007
Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain
Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain
HSMN NewsFeed - 10 Oct 2007
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
HSMN NewsFeed - 8 Oct 2007
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
HSMN NewsFeed - 17 May 2007
Celladon and Targeted Genetics Initiate Phase I Clinical Trial of MYDICAR(TM) in Patients With Heart Failure
Celladon and Targeted Genetics Initiate Phase I Clinical Trial of MYDICAR(TM) in Patients With Heart Failure
HSMN NewsFeed - 24 Apr 2007
Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease
Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease
HSMN NewsFeed - 10 Apr 2007
Amarin Appoints Declan Doogan to New Position of President-Research and Development
Amarin Appoints Declan Doogan to New Position of President-Research and Development
HSMN NewsFeed - 3 Apr 2007
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
HSMN NewsFeed - 8 Mar 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
HSMN NewsFeed - 27 Feb 2007
Targeted Genetics Responds to Litigation Release SEC V. Crestview Capital Partners, LLC and Stewart R. Flink
Targeted Genetics Responds to Litigation Release SEC V. Crestview Capital Partners, LLC and Stewart R. Flink
HSMN NewsFeed - 8 Feb 2007
Polyanalgesic Consensus Panel Issues New Guidelines for Pain Management via Intraspinal Infusion
Polyanalgesic Consensus Panel Issues New Guidelines for Pain Management via Intraspinal Infusion
HSMN NewsFeed - 5 Feb 2007
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
HSMN NewsFeed - 30 Jan 2007
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
HSMN NewsFeed - 19 Dec 2006
PsychoGenics Announces Drug Discovery and Development Agreement With Eli Lilly and Company
PsychoGenics Announces Drug Discovery and Development Agreement With Eli Lilly and Company
HSMN NewsFeed - 3 Oct 2006
B. Braun Awarded Major Home Infusion Pump Contract by Coram Specialty Infusion Services
B. Braun Awarded Major Home Infusion Pump Contract by Coram Specialty Infusion Services
HSMN NewsFeed - 28 Sep 2006
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
HSMN NewsFeed - 21 Sep 2006
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
HSMN NewsFeed - 14 Sep 2006
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
HSMN NewsFeed - 22 Aug 2006
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
HSMN NewsFeed - 1 Jun 2006
Second Generation Cervical Artificial Disc Kicks Off Multiple U.S. Surgeries in Research Study Launch
Second Generation Cervical Artificial Disc Kicks Off Multiple U.S. Surgeries in Research Study Launch
HSMN NewsFeed - 4 May 2006
Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline
Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline
HSMN NewsFeed - 22 Mar 2006
Avicena Compound Receives Orphan Drug Designation for Huntington's Disease
Avicena Compound Receives Orphan Drug Designation for Huntington's Disease
HSMN NewsFeed - 14 Mar 2006
Avicena Announces Promising Phase II Results From Parkinson's Disease Trial
Avicena Announces Promising Phase II Results From Parkinson's Disease Trial
HSMN NewsFeed - 28 Feb 2006
Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
HSMN NewsFeed - 20 Jan 2006
Stem Cell Therapeutics Corp. Announces Selected Upcoming Development Milestones
Stem Cell Therapeutics Corp. Announces Selected Upcoming Development Milestones
HSMN NewsFeed - 3 Jan 2006
Amarin Licenses Phase IIb/III Drug for the Treatment of Fatigue in Multiple Sclerosis to Multicell Inc.
Amarin Licenses Phase IIb/III Drug for the Treatment of Fatigue in Multiple Sclerosis to Multicell Inc.
Additional items found! 56

Members Archive contains
56 additional stories matching:
Huntington
(Password required)
Huntington
(Password required)